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Mutant U2AF1-expressing cells are sensitive to
pharmacological modulation of the spliceosome
Cara Lunn Shirai1,*, Brian S. White1,*, Manorama Tripathi1,*, Roberto Tapia1, James N. Ley1, Matthew Ndonwi1,
Sanghyun Kim1, Jin Shao1, Alexa Carver1, Borja Saez2, Robert S. Fulton3, Catrina Fronick3, Michelle O’Laughlin3,
Chandraiah Lagisetti4, Thomas R. Webb4, Timothy A. Graubert2 & Matthew J. Walter1
Somatic mutations in spliceosome genes are detectable in B50% of patients with myelo-
dysplastic syndromes (MDS). We hypothesize that cells harbouring spliceosome gene
mutations have increased sensitivity to pharmacological perturbation of the spliceosome. We
focus on mutant U2AF1 and utilize sudemycin compounds that modulate pre-mRNA splicing.
We ﬁnd that haematopoietic cells expressing mutant U2AF1(S34F), including primary patient
cells, have an increased sensitivity to in vitro sudemycin treatment relative to controls. In vivo
sudemycin treatment of U2AF1(S34F) transgenic mice alters splicing and reverts haemato-
poietic progenitor cell expansion induced by mutant U2AF1 expression. The splicing effects of
sudemycin and U2AF1(S34F) can be cumulative in cells exposed to both perturbations—drug
and mutation—compared with cells exposed to either alone. These cumulative effects may
result in downstream phenotypic consequences in sudemycin-treated mutant cells. Taken
together, these data suggest a potential for treating haematological cancers harbouring U2AF1
mutations with pre-mRNA splicing modulators like sudemycins.
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M
yelodysplastic syndromes (MDS) are the most common
adult myeloid malignancy with up to 40,000 new cases
diagnosed each year in the United States1,2. MDS are a
heterogeneous group of clonal haematopoietic stem cell disorders
characterized by peripheral blood cytopaenias and progenitor
expansion; approximately one-third of patients will transform
to a secondary acute myeloid leukaemia (AML) that has a
poor prognosis3. The only curative therapy is bone marrow
transplantation, which is often not an option because of patient
comorbidities3. New treatment approaches are greatly needed.
At least half of all MDS patient bone marrow samples harbour
a mutation in one of several spliceosome genes4–10, highlighting
a potential genetic vulnerability. In addition, spliceosome gene
mutations often occur in the founding clones of MDS tumours,
providing an attractive target for elimination of all tumour
cells10,11. Spliceosome gene mutations are mutually exclusive
of each other in patients4,10–12, implying either a redundancy
in pathogenic function or that a cell cannot tolerate two
spliceosome perturbations at once. With this in mind, we
hypothesized that cells harbouring a spliceosome gene mutation
would have increased sensitivity to further perturbation of the
spliceosome by splicing modulator drugs. To examine this,
we utilized sudemycin compounds that bind the SF3B1
spliceosome protein and modulate pre-mRNA splicing13–15. We
used sudemycin D1 and D6, which are synthetic compounds
that have been optimized by several rounds of medicinal
chemistry for their potent in vivo antitumour activity13. We
examined the sensitivity of spliceosome mutant cells to
sudemycin treatment, focusing on mutations in the spliceosome
gene U2AF1, which have been identiﬁed in 11% of MDS patients,
utilizing the S34F missense mutation most commonly found
in our studies4,5. Mutant U2AF1(S34F) expression has been
shown by our group and others to cause altered pre-mRNA
splicing in a variety of cell types, as well as altered haematopoiesis
and pre-mRNA splicing in mice4,5,16–19.
In this manuscript, we provide evidence that U2AF1(S34F)-
expressing cells are sensitive to the splicing modulator drug
sudemycin. Haematopoietic cells expressing mutant U2AF1
show reduced survival and altered cell cycle in response to
sudemycin D6 in vitro. In vivo treatment of U2AF1(S34F)
transgenic mice with sudemycin results in an attenuation
of mutant U2AF1-induced haematopoietic progenitor cell
expansion that is associated with increased cell death. In addition,
unsupervised analysis of whole-transcriptome sequencing
(RNA-seq) ﬁnds that sudemycin D6 perturbs RNA splicing in
both mutant U2AF1(S34F)- and U2AF1(WT)-expressing bone
marrow cells; however, sudemycin D6 treatment further
modulates mutant U2AF1(S34F)-induced splicing changes to
create cumulative effects on cells in vivo. The cumulative
RNA-splicing effects of sudemycin and mutant U2AF1 may
contribute to the downstream phenotypic consequences we
observe in vivo.
Results
Sudemycin alters RNA splicing in primary human CD34þ cells.
We ﬁrst examined the pre-mRNA splicing alterations induced
by sudemycin D6 in primary human haematopoietic cells.
We treated CD34þ haematopoietic progenitor cells isolated
from human umbilical cord blood with 1,000 nM of sudemycin
D6 or dimethylsulphoxide (DMSO) vehicle control for 6 h
in vitro and performed whole-transcriptome (RNA-seq) analysis
(n¼ 6 each, Supplementary Fig. 1). We identiﬁed robustly altered
gene expression and pre-mRNA splicing patterns induced
by sudemycin, as shown by unsupervised clustering of samples
using expressed genes (Fig. 1a) and pre-mRNA splice junctions
(Fig. 1b), respectively. Our analysis identiﬁed 1,030 differentially
expressed genes (FDRo5%, |log2FC|41) and 18,833 dysregu-
lated splicing events (FDRo5%, |delta per cent spliced in or
PSI (DC)|410%, Supplementary Data 1 and 2, respectively) that
discriminated between sudemycin D6-treated samples and
controls. Sudemycin D6 treatment induced altered pre-mRNA
splicing with a bias towards increased exon skipping and intron
retention (Fig. 1b). However, there was no apparent bias in
the sequence motif surrounding splice acceptor sites of cassette
exons that were alternatively spliced (Fig. 1c), in contrast to
previously observed biases in sequences surrounding alternatively
spliced junctions induced by expression of mutant spliceosome
proteins U2AF1, SF3B1 and SRSF2 (refs 16–25).
To determine whether particular pathways are enriched
for splicing perturbations, we applied GOseq to 6,278 genes with
junctions signiﬁcantly altered by sudemycin D6 treatment
(FDRo5%, |log2FC|42). While pathway enrichment was mini-
mal (enrichment scores o2), GOseq analysis indicated that
pathways involved in pre-mRNA splicing, RNA processing and
transport, cell cycle, as well as ATPase and helicase activity were
enriched in splice junctions altered by sudemycin D6 treatment
(FDRo10%; Supplementary Data 3). Genes with sudemycin-
altered expression were enriched in pathways involved in receptor
and signal transduction activities (FDRo10%; Supplementary
Data 4).
Mutant U2AF1 cells have increased sensitivity to sudemycin.
To examine the effects of sudemycin D6 on haematopoietic
cells expressing mutant U2AF1, we generated K562 human
erythroleukaemia and OCI-AML3 AML cell lines that have stably
integrated doxycycline-inducible, FLAG-tagged U2AF1(S34F) or
FLAG-tagged U2AF1(WT) to control for U2AF1 overexpression
(Supplementary Fig. 2a,b for K562; Fig. 2c,d for OCI-AML3).
Mutant U2AF1(S34F)-expressing K562 cells showed reduced
survival and lower IC50 (Po0.0001, extra sum-of-squares F-test)
relative to uninduced mutant U2AF1(S34F) and U2AF1(WT)-
expressing control cells (Fig. 2a). These effects were also observed
in human OCI-AML3 cell lines expressing mutant U2AF1(S34F)
compared with U2AF1(WT)-expressing cells and other control
cells (Po0.003, extra sum-of-squares F-test; Fig. 2b). Reduced
survival of K562 cells in the presence of sudemycin D6 is
associated with an altered cell cycle proﬁle: U2AF1(S34F)-
expressing K562 cells had a decrease of cells in the S-phase and an
increase of cells in the sub-G0/G1 and G2/M phases (Fig. 2c).
Furthermore, MDS or AML cells with U2AF1(S34F) mutations
treated in vitro with sudemycin D1, a sudemycin compound very
similar to D6, showed an increased sensitivity to sudemycin
(reduced S-phase) relative to control MDS/AML cells without
spliceosome gene mutations (Fig. 2d). In contrast, treatment of
MDS/AML patient cells with the chemotherapeutic drug
daunorubicin (not predicted to disrupt splicing) showed no
speciﬁcity for mutant U2AF1(S34F) samples compared with
controls (Supplementary Fig. 2e). In addition, human CD34þ
cells expressing U2AF1(S34F) showed increased sensitivity to
another splicing modulator drug (E7107) similar to sudemycin
(Supplementary Fig. 2f).
Sudemycin reduces mutant U2AF1 progenitor expansion in vivo.
We next examined the effect of sudemycin treatment in vivo
on mutant U2AF1(S34F)-induced phenotypes using our
previously described U2AF1(S34F) transgenic mouse model19.
We induced U2AF1(S34F) or U2AF1(WT) transgenes for 7 days
in the bone marrow cells of transplanted mice (to study haema-
topoietic cell-intrinsic effects) and treated mice concurrently
with sudemycin D6 (50mg kg 1 per day) or vehicle for 5 of
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those days; see schema (Fig. 3a). Sudemycin D6 treatment of
transplanted mice showed an attenuation of the previously
described19 mutant U2AF1(S34F)-induced haematopoietic
progenitor cell expansion by colony-forming unit (CFU-C)
assay (Fig. 3b) and by ﬂow cytometry for lineage-, c-Kitþ ,
Sca1þ (KLS) cells (Fig. 3c) when compared with control U2AF1
mutant mice treated with vehicle and mice transplanted with
U2AF1(WT)-expressing bone marrow. The attenuation of
mutant U2AF1-induced progenitor expansion by sudemycin-
treated mice is associated with increased Annexin Vþ staining of
KLS cells (Fig. 3d).
Sudemycin and U2AF1 (S34F) splicing effects can be cumulative.
To investigate the potential genotype-speciﬁc effects of sudemycin
treatment on splice isoform expression, we performed
whole-transcriptome sequencing (RNA-seq) on U2AF1(S34F)- and
U2AF1(WT)-recipient mouse bulk bone marrow cells following
in vivo U2AF1 transgene induction and treatment with sudemycin
D6 (50mgkg 1 per day for 5 days) or vehicle (Supplementary
Fig. 3a,b). RNA was harvested 18h after the last drug treatment
(similar to described above; schema shown in Fig. 3a). Sudemycin
D6 treatment at this dose and schedule does not markedly skew the
mature lineage distribution within bulk bone marrow of mutant or
wild-type (WT) U2AF1 transgenic mice (Supplementary Fig. 3c).
Using an unsupervised approach, we observed that sudemycin D6
perturbs splicing in both mutant U2AF1(S34F) and U2AF1(WT)-
expressing bone marrow cells (Supplementary Data 5–9); this is
visualized by the segregation of samples according to genotype and
treatment within a principal component analysis (PCA)
of cassette exon (Fig. 4a) and retained intron (Supplementary
Fig. 4a) splicing events. Furthermore, the splicing bias observed
in human cells treated with sudemycin (described above) is
recapitulated in U2AF1(WT) mouse cells: sudemycin D6 induces
exon skipping more often than exon inclusion relative to vehicle
(388 of 657 signiﬁcant (FDRo10%, |DC|41%) events;
Po2 10 6, one-sided binomial test), as well as intron retention
more often than removal (98 of 145 signiﬁcant (FDRo10%,
Vehicle



































































































































































































Figure 1 | Sudemycin D6 alters gene expression and pre-mRNA splicing in primary human CD34þ haematopoietic cells. Whole-transcriptome
(that is, RNA-seq) analysis was performed on CD34þ cells isolated from human umbilical cord blood following treatment of samples with 1,000nM
Sudemycin D6 or DMSO vehicle for 6 h (n¼ 6). Unsupervised hierarchical clustering of (a) expressed genes and (b) splice junctions. Skipped exons (SE,
green) and retained introns (RI, purple) event types are visualized. Values are z-scores computed from regularized logarithm values for genes and from per
cent spliced in (PSI or C) values for splicing events. (c) Intronic sequence contexts of cassette exon 30 splice sites skipped more often in sudemycin- relative
to vehicle-treated cells (FDRo5%, |DC|410%, left panel) or skipped more often in vehicle-relative to sudemycin-treated cells (FDRo5%, |DC|410%,
middle panel), along with a context of unperturbed control exons (FDR450%, |DC|o0.1%, right panel). Position is relative to the ﬁrst base in the exon.
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|DC|41%) events; Po1.4 10 5, one-sided binomial test).
As in human CD34þ cells, the sudemycin-induced
changes were not associated with an apparent sequence motif
(Supplementary Fig. 4b); however, we did observe the previously
reported increase in a T in the  3 position of the intronic 30 splice
acceptor site of exons more commonly skipped in mutant
U2AF1(S34F) cells16–19 (Supplementary Fig. 4c). In addition,
we deﬁned ‘high-conﬁdence’ sets of U2AF1(S34F) and sudemycin
targets, and subsets of those had a high validation rate
in orthogonal experimental (NanoString26) and statistical
(edgeR27) platforms (Supplementary Information and Supple-
mentary Data 10 and 11).
Next, we examined potential interactions between the drug
and mutation within cells, focusing on exon skipping events.
Along these lines, we observed that the exon skipping effects
induced by sudemycin D6 (relative to vehicle) within
U2AF1(WT)-expressing cells are highly correlated with the
drug effects in U2AF1(S34F)-expressing cells (R2¼ 0.8,
Po2.2 10 16, F-test, events signiﬁcant in both comparisons
(FDRo10%), Fig. 4b). The vast majority of these events
are concordant (in the same direction of induced change with
similar magnitude) across genotypes (slope of the regression
line¼ 0.75), suggesting that sudemycin treatment results
in similar splicing alterations in these targets in both mutant
U2AF1 and WT cells (Fig. 4b). We further assessed
drug/genotype interaction using a statistical linear model: of
32,529 dysregulated splicing events (across all event types),
only 136 showed statistically signiﬁcant evidence of interaction
(that is, synergy or antagonism; DEXSeq, FDRo10%). However,
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Figure 2 | Mutant U2AF1(S34F)-expressing cells display increased sensitivity to sudemycin D in vitro. (a) K562 cells (n¼6 for control groups, n¼9 for
U2AF1(S34F) treated with doxycycline) or (b) OCI-AML3 cells (n¼ 3 for all groups) with stably integrated, doxycycline-inducible U2AF1(WT) or mutant
U2AF1(S34F) were cultured with increasing concentrations of sudemycin D6 concurrently with doxycycline (250 ngml 1, where indicated) for
5 days following 2 days of initial induction of mutant or WT U2AF1; total cell numbers were measured. The surviving fraction of cells is shown.
IC50, inhibitory concentration at 50% of maximum cell survival. (c) K562 cell cycle phases were determined using BrdU/7AAD (n¼ 3, representative of
two experiments; *Po0.05, **Po0.01, ***Po0.001 statistics calculated with two-tailed t-tests of MUT þ dox samples compared with each control group
at a given concentration of sudemycin D6, and the least signiﬁcant value is given for each group; mean values with s.d. shown). (d) Primary human MDS or
AML cells (both mutant U2AF1(S34F) samples (n¼ 3) and those wild type for U2AF1 (n¼ 6)) or normal umbilical cord blood CD34þ cells (n¼ 1) were
cultured on irradiated HS27 stroma, and proliferation (EdU incorporation) was measured after 3 days of exposure to increasing concentrations of
sudemycin D1.
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junction in the same direction (for example, both increasing
exon skipping), this results in a cumulative effect in a sudemycin-
treated mutant cell that is greater than the effect induced
by sudemycin treatment of WT cells (indicated by red and
blue colour in Fig. 4b–d). As an example, U2AF1(S34F)
expression induces increased exon skipping in a 4932438A13Rik
splice junction compared with U2AF1(WT) in vehicle-treated
cells (DC¼ 0.205, middle two columns in Fig. 4c). Sudemycin
D6 also increases exon skipping of the same junction in
U2AF1(WT) (DC¼ 0.188) and U2AF1(S34F) (DC¼ 0.204) cells
(that is, sudemycin-induced exon skipping is independent of
genotype; Fig. 4c). Therefore, as expected, the cumulative
effect induced by both mutation and drug treatment
(DC¼ 0.409) exceeds the individual effects of mutant U2AF1
expression or sudemycin treatment alone, ultimately resulting in
different levels of exon skipping in sudemycin-treated cells
expressing mutant U2AF1 versus WT cells (Fig. 4c). The
cumulative effect of mutation and drug can also be observed in
splicing events that result in increased exon inclusion (Fig. 4d).
Together, these data signify that the effects of sudemycin and
U2AF1(S34F) on splicing in the same cell can be cumulative—
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Figure 3 | Sudemycin D6 treatment attenuates mutant U2AF1-induced progenitor cell expansion in U2AF1(S34F) transgenic mice. (a) Schema of
sudemycin treatment of transgenic mice in vivo. Doxycycline-inducible U2AF1(S34F) or U2AF1(WT) transgenic mouse bone marrow was transplanted into
recipient mice. Intrajugular (IJ) catheters were placed for IV drug infusions, which were performed over 4 h for 5 days. (b) Haematopoietic progenitor
CFU-C colony-forming assay and (c) ﬂow cytometry for haematopoietic stem and progenitor (HSPC) cell surface markers (c-Kitþ , lineage , Sca1þ , KLS,
right panel) on U2AF1(WT)- or (S34F) mutant-recipient mouse bone marrow following treatment is shown (n¼ 6 for both U2AF1(WT) conditions, n¼ 7
for vehicle-treated U2AF1(S34F), n¼ 11 for sudemycin D6-treated U2AF1(S34F)). (d) Annexin Vþ KLS cells were quantiﬁed in the bone marrow of mice
following in vivo sudemycin treatment as described above (n¼ 7–9). Data pooled from two independent experiments (b–d); statistics calculated using
two-tailed t-tests for each comparison shown; mean values with s.d. shown.
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Figure 4 | Sudemycin D6 treatment alters splicing and gene expression in mutant U2AF1-haematopoietic cells. RNA sequencing and transcriptome
analysis was performed on RNA harvested from mouse bone marrow cells expressing mutant U2AF1(S34F) or U2AF1(WT) following treatment of
mice with sudemycin D6 (50mg kg 1) or vehicle control for 5 days (n¼ 5 per genotype and treatment). (a) PCA of normalized expression of skipped
cassette exon events. (b) Correlation between sudemycin-induced changes relative to vehicle treatment in cassette exons of U2AF1(WT) cells
DCWTSud¼ CWT;SudCWT;Veh
 
(FDRo10%) and of mutant U2AF1(S34F) cells DCMTSud¼ CMT;SudCMT;Veh
 
(FDRo10%; R2¼0.8; Po2.2 10 16, F-test).
Dashed line indicates similar effects in U2AF1(WT) and U2AF1(S34F) cells DCWTSud¼DCMTSud
 
. Colour scale indicates cumulative splicing changes of
U2AF1(S34F) expression with sudemycin treatment (that is, DCSudMT¼ CMT;SudCWT;Sud), with red being a positive change, blue being a negative change,
and white being no difference between sudemycin-treated U2AF1(S34F) and U2AF1(WT) cells. (c,d) Delta PSI (DC) for each condition on the horizontal
axis relative to vehicle-treated U2AF1(WT) cells ((CWT;Veh)¼0) for events that are signiﬁcantly dysregulated across all ﬁve comparisons (see
Supplementary Methods), have concordant sudemycin-induced dysregulation across genotype (that is, DCWTSud and DC
MT
Sud have the same direction), and in
which the sudemycin effect is exacerbated by mutation. The cumulative effect on cassette exons induced by both mutant U2AF1 and sudemycin D6
treatment relative to vehicle-treated WT cells, DCcum, may result in increased exon skipping (positive values, c) or increased exon inclusion (negative
values, d). (e) PCA of normalized expression of expressed genes. (f) Correlation between sudemycin-induced changes relative to vehicle treatment
(expressed as log2 fold changes, FDRo10%) in U2AF1(WT) and U2AF1(S34F) cells (R2¼0.8; Po2.2 10 16, F-test). Dashed line indicates log2 fold
changes induced by sudemycin are the same in U2AF1(WT) and U2AF1(S34F) cells. Colour scale indicates cumulative contribution of mutant U2AF1
expression to sudemycin-induced gene expression changes, that is, log2 fold change of gene expression altered by sudemycin in mutant U2AF1(S34F) cells
relative to U2AF1(WT) cells, with red being a positive change, blue being a negative change and white being no difference. U2AF1 mutant (MT), sudemycin
D6 (Sud), U2AF1 WT, vehicle (Veh), principal component 1 (PC1), principal component 2 (PC2), principal component 3 (PC3), per cent spliced in (PSI, C).
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Sudemycin induces gene expression alterations. Sudemycin
treatment in vivo also results in altered gene expression in
mutant U2AF1 mouse bone marrow cells compared with
U2AF1(WT)-expressing control cells (Supplementary Data 12).
As with splicing alterations, mouse bone marrow samples
segregate by genotype and by treatment in an unsupervised
analysis of gene expression (Fig. 4e). As seen at the junction
level, there is a high-degree of correlation between sudemycin-
induced, gene-level effects (direction and magnitude relative
to vehicle) across mutant and WT genotypes (R2¼ 0.8,
Po2.2 10 6, F-test, events signiﬁcant (FDRo10%) in both
comparisons, Fig. 4f). We also observed cumulative effects
of mutation and drug on gene expression (colour in Fig. 4f),
which may result in downstream cellular pathway changes.
Using GOseq, we identiﬁed pathways that were most enriched
for differentially expressed genes in mutant cells treated
with sudemycin D6 relative to the other genotype and treatment
groups (FDRo10%). We found mutant cells treated with
sudemycin D6 were enriched in biologic pathways related
to immune and inﬂammatory responses, antigen processing
and presentation, cytokine production, leukocyte differen-
tiation, cell death and apoptotic processes, when compared
with the other genotype and treatment groups (Supplementary
Data 13).
Discussion
We provide evidence suggesting that U2AF1(S34F)-expressing
cells are sensitive to the splicing modulator drug sudemycin.
Haematopoietic cells expressing mutant U2AF1 have reduced
survival and cell cycle changes following sudemycin D6 treatment
in vitro. In vivo, sudemycin D6 is capable of attenuating mutant
U2AF1-associated expansion of haematopoietic progenitors
in transgenic mice that is associated with increased cell death.
In addition, while the effects of sudemycin D6 treatment on
splicing and gene expression can be independent of the effects of
mutant U2AF1 expression, sudemycin D6 treatment can also
modulate splicing changes induced by mutant U2AF1(S34F)
to create cumulative effects on cells in vivo. Together, these
data indicate that mutant U2AF1(S34F)-expressing cells may
have a therapeutic vulnerability to splicing modulator drugs such
as sudemycin.
Previous studies using splicing modulator drugs, as well as
non-pharmacological methods to target splicing factors, have
indicated that the spliceosome is a promising therapeutic target
for many cancer cell types13,14,28–31. Recent studies have
suggested that cancers with spliceosome gene mutations may
have an increased sensitivity to splicing modulator drugs
like sudemycin;32–34 this study provides further evidence to
support this hypothesis. Speciﬁcally, we show that mutant U2AF1
cells are sensitive to in vivo treatment with sudemycin. Using
unbiased RNA-seq, we show that sudemycin D6 has effects
on mutant U2AF1-associated splicing changes, resulting in
different levels of transcript isoforms in cells expressing mutant
U2AF1 compared with WT following sudemycin treatment.
Ultimately, cumulative changes in isoform expression could be
the cause of the mutant U2AF1-speciﬁc responses to sudemycin
treatment that we observe in vitro and in vivo. Identiﬁcation
of critical downstream targets of sudemycin in vivo will likely
require examination of various cellular populations within
the bone marrow (including haematopoietic stem and
progenitor cells) and harvesting cells at more immediate
time points following drug treatment—both limitations of the
current study. Future studies will focus on generating mutant
U2AF1-expressing leukaemias in mice to test the efﬁcacy of
sudemycin on fully transformed haematopoietic tumours, as has
recently been reported using E7107 to treat Srsf2(P95H)-
expressing leukaemias33.
Our data and others highlight several possible mechanisms
for the sensitivity of spliceosome mutant samples to splicing
modulator therapy. Pathway analysis of differentially expressed
genes induced by sudemycin revealed enrichment in inﬂamma-
tory signalling pathways. This is consistent with the enrichment
in biological pathways related to cytokine and immune signalling
observed following in vivo treatment of Srsf2(P95H) mutant
mice with the splicing modulator E7107 (ref. 33), raising the
possibility that spliceosome mutant-speciﬁc phenotypes observed
in mice following splicing modulator drug treatment may be
driven by an altered inﬂammatory response in mutant cells.
Whether the altered inﬂammatory response in mutant cells
treated with splicing modulator drugs is a direct result of mutant-
altered splicing or gene expression could be explored in future
studies. Alternatively, it is also possible that the cumulative effect
of sudemycin and mutant U2AF1 expression on pre-mRNA
splicing may simply create a state of ‘spliceosome sickness’ in
cells by exceeding a tolerable threshold of splicing perturbations
and their downstream consequences. Along these lines, other
splicing modulator drugs have been shown to cause increased
intron retention, R loop formation, DNA damage and cell
death28,29,31,35. Spliceosome gene mutations and splicing
modulator drugs may both induce these consequences in a
cell, and the cumulative effect of the drug and mutation may
create a toxic intracellular milieu.
Exploring the clinical utility of splicing modulator therapies
in MDS patients with spliceosome mutations who have failed
current therapies is warranted and currently being pursued
(NCT02841540), as these patients have few treatment options.
Whether excessive toxicity will occur in WT cells treated
with newer splicing modulators is a major question. Initial
phase I clinical trial studies using a splicing modulator,
E7107, showed toxicities in some patients with solid tumours,
including ocular toxicity (NCT00459823, NCT00499499).
The mechanism for the toxicity is not known. Moving forward,
mutant U2AF1 and other preclinical models of spliceosome
mutations will be valuable in further testing the in vivo efﬁcacy
and toxicity of drugs that modulate splicing through various
mechanisms. Collectively, our data suggest that a mutant
splicing factor together with a splicing modulator drug like
sudemycin may create a unique cellular toxicity that could be
exploited for therapeutic purposes.
Methods
Isolation and drug treatment of CD34þ haematopoietic cells. Mononuclear
cells from human umbilical cord blood were separated by Ficoll gradient
centrifugation (each n value is a pooled set of four individual umbilical
cord blood samples). CD34þ cells were enriched using autoMACS-positive
selection (CD34 MicroBead Kit, Miltenyi Biotec) according to the
manufacturer’s instructions to achieve 490% purity of CD34þ cells.
Following isolation, CD34þ cells were cultured in X-Vivo media
(Lonza) with cytokines (SCF, FLT3L, IL3 and TPO) overnight. For whole-
transcriptome sequencing with sudemycin, either sudemycin D6 (1,000 nM)
or the vehicle DMSO was added to cells for 6 h, and cells were then
harvested for RNA. Tissue acquisition was performed per protocol
approved by the Washington University School of Medicine Institutional
Review Board.
RNA-seq of CD34þ cells treated with sudemycin. RNA was isolated
from human CD34þ cells using the miRNEasy Kit (Qiagen), and removal
of genomic DNA was performed via a Turbo DNA-Free Kit (Ambion).
Ribosomal RNA was removed using Ribozero (Epicenter), followed by
cDNA preparation and generation of stranded libraries using the TruSeq
Stranded Total RNA Sample Prep Kit (Illumina). Sequencing was performed
on the HiSeq2500 platform (Illumina) to generate 2 125 bp paired-end
reads. RNA-seq data were deposited in NCBI dbGAP (phs000159.v9).
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RNA-seq analysis of human CD34þ cells treated with sudemycin. Analysis of
(stranded) RNA-seq data generated from primary human CD34þ haematopoietic
cells treated with sudemycin D6 was performed using the genome modelling
system36. Reads were aligned to the human genome (hg19/NCBI build 37)
using TopHat37 version 2.0.8, with annotations provided by Ensembl38
version 67. All downstream bioinformatic and statistical analyses, including
calculation of P values using Fisher’s exact test and simulation, were performed
in R39 and python. The heatmap of gene expression was created using normalized
expression values output by DESeq2 package (version 1.6.3 (ref. 40)) that was
subsequently z-scored. DESeq2 was used to detect differentially expressed
genes, and gene-set enrichment analysis was then performed by applying
GOseq41 (version 1.18.0) to differentially expressed genes (FDRo5%, |log2FC|41,
DESeq2). Additional details of RNA-seq analysis of gene expression are
further described in the Supplementary Methods.
Alternative splicing events were computed via rMATS42 (version 3.0.8).
We generated the heatmap of splice junctions using ‘per cent spliced in’
(PSI or C) values for exon skipping and intron retention events. For downstream
analyses, namely reported dysregulated events and visualization of sequence
contexts below, P values for events passing the ﬁlter were re-adjusted for
multiple hypothesis testing using the method of Benjamini and Hochberg43.
A positive DPSI value indicates an event that was spliced in more often in the
vehicle-treated relative to the sudemycin-treated samples. Sequence contexts of
splice sites in exon skipping and intron retention events were visualized using
seqLogo version 1.32.1. Dysregulated events visualized were those with
|DPSI|410% and having a post-ﬁltering re-adjusted FDRo5% from rMATS.
Dysregulated splicing junctions were determined by DEXSeq4 version 1.12.2.
Only expressed junctions were analysed, and gene-set enrichment analysis was
performed by applying GOseq to dysregulated junctions (FDRo5%, |log2FC|41,
DEXSeq). All of these are described in more detail in the Supplementary Methods.
Creation of inducible U2AF1(S34F) and U2AF1(WT) cell lines. Doxycycline-
inducible FLAG-tagged WT U2AF1 or FLAG-tagged mutant U2AF1(S34F)
lentiviral expression plasmids were previously described4, and lentivirus was
generated in 293T cells with the packaging plasmids pMD-G, pMD-Lg and
REV. Concentrated virus (multiplicity of infection (MOI) of 3 for K562, MOI of
5 for OCI-AML3) was used to transduce K562 cells (ATCC, CCL243) or
OCI-AML3 (DSMZ, ACC 582). Transduced cells (marked by green ﬂuorescent
protein) were isolated by ﬂow cytometry cell sorting. Expression of mutant or
WT U2AF1 was induced using the indicated concentrations of doxycycline hyclate
(Sigma, St Louis, MO) in water.
Cell line counting and BrdU incorporation assays. K562 (or OCI-AML3) cells in
culture were seeded at B200,000 cells per ml with different concentrations of
Sudemycin D6 (or with DMSO control) following 48 h of initial doxycycline
treatment to induce mutant U2AF1(S34F) or U2AF1(WT) expression. Cells were
counted on Days 0, 3 and 5 of drug treatment using ﬂow cytometry counting
particles (Spherotech) as per the manufacturer’s recommendations, along with
propidium iodide (Millipore) to exclude dead cells from counts. Day 5 data were
graphed in Graphpad Prism (Graphpad Software Inc.) using a nonlinear regression
best ﬁt line of the log (drug) versus response for each genotype and treatment.
Statistical differences between curves were examined by the extra sum-of-squares
F-test function in Graphpad Prism. For K562 cells, 5-bromodeoxyuridine
(BrdU) incorporation was performed using the BrdU Flow Kit (APC, #559619,
BD Biosciences) as per the manufacturer’s instructions using a 45min pulse of
BrdU of cells in culture on Day 5 of drug treatment.
Culture of MDS/AML cells and EdU incorporation assay. Primary MDS and
AML cells were cultured on irradiated (4,000 cGy) HS27 stroma as described
previously45. Brieﬂy, MDS or AML cells were cultured on stroma for 2–3 days
and then treated with increasing doses of sudemycin D1 (or daunorubicin in
Supplementary Information). MDS and AML cells were cultured with drug
for 3 days and analysed for cell proliferation by EdU incorporation assay
(Invitrogen) via ﬂow cytometry. All experiments were performed on 96-well
plates. Studies were performed per protocol approved by the Washington
University School of Medicine Institutional Review Board and with patients’
consent for sample use.
Murine bone marrow transplant and drug infusion. To generate mice for
each experiment, 1 106 transgenic mouse donor bone marrow cells from two
to three mice pooled (CD45.2) were transplanted into at least ﬁve lethally
irradiated (1,100 rads) congenic WT recipient mice (C57BL/6 129S4Sv/Jae)F1
(CD45.1/CD45.2) per genotype, as previously described19. Donor mice were
between 8 and 12 weeks of age, and recipient mice ranged from 6 to 12 weeks
of age; donor and recipient mice were sex-matched (both sexes were used in
experiments). Donor chimerism was conﬁrmed Z6 weeks post transplantation
to ensure engraftment of transgenic bone marrow. Post-engraftment, intrajugular
catheters were surgically placed for intravenous drug infusions of mice over
4 h daily for 5 days with either sudemycin D6 (50mg kg 1) or vehicle control
(HP-b-CD (2-hydroxypropyl)-b-cyclodextrin in phosphate buffer pH 7.4). This
dose was determined by prior studies13. Mice received doxycycline chow to
induce U2AF1(S34F) or U2AF1(WT) transgene on the day of surgery, and
drug infusion began 2 days later. Mice of each group were randomly selected
for treatment with sudemycin or vehicle control. Investigators were not blinded
to the group allocation during the experiment or analysis. Animals were
excluded from analysis if their catheters did not remain patent during the
entire treatment period. Mice were euthanized for analysis the day following the
last drug infusion. Sample sizes for experiments were chosen to allow for
statistical comparison between groups. All mouse procedures were performed
according to the protocols approved by the Washington University Animal
Studies Committee.
Mouse haematopoietic progenitor cell assay. Methylcellulose progenitor
CFU-C assays were performed using Methocult GF M3434 (Stem Cell
Technologies). Bulk bone marrow cells were obtained from experimental mice, and
red blood cells were lysed before plating of 10,000 bone marrow cells per 1.3ml
media; each sample was evaluated in duplicate. Progenitor colonies (deﬁned as
Z40 cells per colony) were counted following 7 days culture at 37 C with
5% CO2.
Mouse haematopoietic cell ﬂow cytometry. For ﬂow cytometry, all
antibodies are from eBioscience (unless indicated), and catalogue number
provided (if available). For haematopoietic progenitor/stem cells, we used the
following antibodies (volume of antibody used in 200 ml of ﬂuorescence-activated
cell sorting (FACS) buffer for staining is also indicated): CD45.1-APC (#17-0453,
3 ml), CD45.2-PE (#12-0454, 3 ml), Biotin-conjugated lineage (Gr-1 (#13-5931,
0.25 ml), Cd3e (#13-0032, 0.5 ml), B220 (#13-0452, 0.5 ml), Ter119 (#13-5921, 0.5 ml)
and CD41(#13-0411, 1 ml)), streptavidin secondary-eFluor605NC,
c-Kit-APCeFluor780 (#47-1172, 1.5 ml), Sca1-PerCP-Cy5.5 (#45-5981, 0.5 ml).
Flow cytometry for Annexin Vþ staining of KLS cells was performed
following initial staining of KLS cells as described above using Annexin
V-APC (2.5 ml, BD Biosciences, #550474) incubated in 1 Annexin V binding
buffer (BD Biosciences). All other incubations occurred in FACS buffer.
All ﬂow cytometry analyses were performed using FACScan or Gallios
cytometers (BD Biosciences) and analysed using the FlowJo software
(FlowJo, LLC, Ashland, OR, USA).
RNA-seq of mouse bone marrow cells in vivo. RNA was isolated and prepared
as described above for human cells, using the miRNEasy Kit (Qiagen) followed
by removal of genomic DNA via a Turbo DNA-Free Kit (Ambion) and ribosomal
RNA using Ribozero (Epicenter). The cDNA preparation and generation of
stranded libraries was performed using the TruSeq Stranded Total RNA
Sample Prep Kit (Illumina). Sequencing was performed on the HiSeq2500
platform (Illumina) to generate 2 126 bp paired-end reads. The RNA-seq
data have been deposited in NCBI’s Gene Expression Omnibus46 and are
accessible through the GEO Series accession number GSE89834.
RNA-seq analysis of mouse bone marrow cells in vivo. Analysis of (stranded)
RNA-seq data generated from U2AF1(S34F) and U2AF1(WT) murine cells
treated with sudemycin D6 or vehicle was performed similarly to the human
CD34þ cell analysis described above, with some differences as follows.
Alignment again utilized genome model system, and reads were aligned to the
mouse genome (mm9/NCBI build 37). ‘Per cent spliced in’ (PSI or C) values
were calculated for all four conditions ({U2AF1(S34F), U2AF1(WT)}
 {sudemycin D6, vehicle}) using rMATS. PCA was performed independently
on events annotated by rMATS as skipping cassette exons or retaining introns
using the z-scored C values of these events.
To quantitate the simultaneous effect of treatment and genotype for each
splicing event, we calculated the change in per cent spliced in values for the
four pairwise comparisons in which the genotype (alternately, treatment) was the
same in the pair, but in which the treatment (alternately, genotype) differed.
We refer to the unchanged condition as the ‘context’ and to the two conditions
that differ as ‘A’ and ‘B’ and denote the corresponding change in the per cent
spliced in values as DCcontextA B ¼ Ccontext;A Ccontext;B . In addition, we deﬁned the
cumulative effect in a mutant, drug-treated cell relative to a WT, vehicle-treated
cell as DCcum¼ CSud;MT CVeh;WT. Each of the ﬁve comparisons described
were evaluated using rMATS, and P values for these events were then adjusted for
multiple hypothesis testing as described above. Scatterplots were then plotted of
cassette exon-skipping events dysregulated by sudemycin in both U2AF1(WT)
and U2AF1(S34F) contexts ( DCWTSudVeh
 41%, DCMTSudVeh
 41%, FDRo10%
in both comparisons). To highlight cumulative cassette exon-skipping effects,
‘trajectories’ comparing C values to the ‘baseline’ CVeh;WT were plotted. Events





 41%, DCCumj j41%,
with FDRo10% in all comparisons) were plotted; the latter condition ensures
that visually discernible differences are statically signiﬁcant and not attributable
to statistical noise. Additional details of this can be found in the
Supplementary Methods.
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Non-additive (that is, super-additive synergistic or sub-additive antagonistic)
interactions between drug and mutation were assessed in DEXSeq by comparing
a generalized linear model that included main effects for drug and mutation with
a second model that additionally included an interaction term representing
drug/mutation synergy or antagonism.
As above, splice site sequence contexts of exon-skipping events dysregulated
by sudemycin D6 ( DCWTSudVeh
 41%, FDRo10%) and corresponding
unperturbed control events ( DCWTSudVeh
 40.1%, FDR450%) were plotted
using seqLogo. Similarly, sequence contexts were displayed for events
dysregulated ( DCVehMTWT
 41%, FDRo10%) or unaffected ( DCVehMTWT
 41%,
FDR450%) by U2AF1(S34F).
At the gene-level, PCA was performed as described above for human
expressed genes. Genes differentially expressed within the above-described ﬁve
conditions were determined via DESeq2. Scatterplots were then made comparing
log2 fold changes of genes dysregulated by sudemycin in both U2AF1(WT) and
U2AF1(S34F) contexts (FDRo10% in both comparisons). Pathways
enriched (FDRo10%) for genes differentially expressed between U2AF1(S34F),
sudemycin-treated cells and U2AF1(WT) and/or vehicle-treated cells were
independently determined in a pairwise manner using GOseq. Again,
expanded details of this approach can be found in the Supplementary Methods.
Data availability. All relevant data generated in this study are available at
data-deposition sites. For human CD34þ cells treated with sudemycin D6 in vitro,
data are available at NCBI dbGAP (phs000159.v9). For transgenic mice
expressing mutant U2AF1(S34F) or U2AF1(WT) and treated with sudemycin
D6 in vivo, data are available at Gene Expression Omnibus (GSE89834).
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